Towards an adequate regulatory framework for bacteriophage therapy; Naar een aangepast regelgevend kader voor bacteriofaag therapie

  • Gilbert Verbeken

Student thesis: Thèse de doctorat

Résumé

Resistance of bacteria against antibiotics just keeps growing. Each year, 25.000 European citizens die because of this. Industry’s pipeline does not contain much new antibiotics. Before the pharmaceutical development of antibiotics, e.g. natural bacteriophages (= bacterial viruses) were commercialised and used to kill pathogenic bacteria. This therapeutic application of natural bacteriophages was called “bacteriophage-therapy”. Today, countries like Poland, Georgia and Russia are still practising bacteriophage-therapy. The European Union and “modern” medicine as a whole needs an urgent return of bacteriophage-therapy as part of its armamentarium to fight bacterial resistance to antibiotics. A European regulatory frame to make a smooth and (tailored) qualitative return of bacteriophage therapy possible is actually lacking. The first goal of this doctoral study is to propose a European regulatory frame that could fit the re-introduction of bacteriophage therapy without losing sight of the safety, quality and efficacy aspects related to the therapeutic use of bacteriophages.
la date de réponse28 sept. 2015
langue originaleAnglais
L'institution diplômante
  • École royale militaire
  • KU Leuven
SuperviseurCarl Ceulemans (Promoteur), Isabelle Huys (Promoteur), Rob Lavigne (Co-promoteur), Carl Ceulemans (Promoteur) & Carl Ceulemans (Promoteur)

Contient cette citation

'